

WEST

Generate Collection

L11: Entry 2 of 5

File: DWPI

Jul 4, 2001

DERWENT-ACC-NO: 2000-271263

DERWENT-WEEK: 200138

COPYRIGHT 2001 DERWENT INFORMATION LTD

TITLE: Treating, preventing or diagnosing cancer by administering antibody specific for the C3b(i) component of complement or nucleic acid encoding it

INVENTOR: CHUNG, L; NARDIN, A ; SOKOLOFF, M M D ; SUTHERLAND, W M ; TAYLOR, R

PATENT-ASSIGNEE: UNIV VIRGINIA PATENT FOUND (UYVIN)

PRIORITY-DATA: 1999US-0123786 (March 11, 1999), 1998US-0099782 (September 10, 1998)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
EP 1112086 A1	July 4, 2001	E	000	A61K039/395
WO 200015259 A1	March 23, 2000	E	073	A61K039/395
AU 9959172 A	April 3, 2000	N/A	000	A61K039/395

DESIGNATED-STATES: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT RO SE SI AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL OA PT SD SE SL SZ UG ZW

APPLICATION-DATA:

PUB-NO	APPL-DATE	APPL-NO	DESCRIPTOR
EP 1112086A1	September 10, 1999	1999EP-0946854	N/A
EP 1112086A1	September 10, 1999	1999WO-US20762	N/A
EP 1112086A1		WO 200015259	Based on
WO 200015259A1	September 10, 1999	1999WO-US20762	N/A
AU 9959172A	September 10, 1999	1999AU-0059172	N/A
AU 9959172A		WO 200015259	Based on

INT-CL (IPC): A61K 38/17; A61K 38/17; A61K 39/395; A61K 39/395; A61K 48/00; A61K 51/10; A61K 101/02; A61K 123/00; G01N 33/574; A61K 101/02; A61K 123/00; A61K 39/395; A61K 38/17

ABSTRACTED-PUB-NO: WO 200015259A

BASIC-ABSTRACT:

NOVELTY - Treatment or prevention of cancer comprises administering an antibody (Ab) to C3b(i), optionally covalently linked to a second molecule (I), or a nucleic acid (II) encoding (Ab).

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following:

(1) a pharmaceutical composition comprising Ab, optionally linked to (I), or

(II);

(2) a pharmaceutical composition containing a bispecific antibody (bAb), specific for both C3b(i) and an effector cell receptor or antigen;

(3) a method for detecting cancer by administering Ab, optionally linked to (I), waiting for the labeled antibody to concentrate at a cancerous site in the subject, determining back ground level, and detecting the labeled antibody in the subject, where detection of the labeled antibody above the background level indicates the presence of a cancer;

(4) a method for detecting cancer, comprising imaging the subject after administration of a labeled Ab, and detecting the labeled antibody localized to a site, which indicates the presence of cancer;

(5) a method for depleting cancer cells from other cells taken from an animal with cancer by in vitro treatment with Ab, optionally linked to (I); and

(6) a kit containing, in one or more containers, Ab, optionally linked to (I).

ACTIVITY - Cytostatic: One million LNCaP prostatic cancer cells were opsonized with normal human serum, then washed and incubated with 2 μ g of 131iodine-labeled antibody 7C12, specific for C3b(i), for 30 minutes at room temperature. Cells were washed again then plated and cell viability determined by MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) staining. Over a 3-6 day period, progressive killing of serum-opsonized cells by the antibody was observed, with proliferation rate about 50% of that for untreated cells.

MECHANISM OF ACTION - After opsonization by immunoglobulin M, C3b(i) serves as a tumor-specific marker, i.e. it is a general target for delivery of therapeutic or diagnostic agent to cancer cells.

USE - The method is used to treat or prevent a very wide range of cancers, especially prostatic cancer, and other, benign, proliferative diseases. Ab, when labeled, are also used to detect cancer, particularly by in vivo imaging, for diagnosis or for monitoring treatment, and Ab can be used to deplete cancer cells, e.g. from bone marrow, particularly in vitro.

ADVANTAGE - Cancer cells carry a very large number of C3b(i) epitopes, about 20000 copies in opsonized prostatic cancer cells, so large amounts of therapeutic agent can be delivered. C3b(i) is only rarely deposited on normal cells, so complement activation should be limited to cancer cells.

ABSTRACTED-PUB-NO: WO 200015259A
EQUIVALENT-ABSTRACTS:

CHOSEN-DRAWING: Dwg.0/8

DERWENT-CLASS: B04 D16 S03
CPI-CODES: B04-G01; B04-G21; B12-K04A1; B14-H01; D05-H09; D05-H11A; D05-H11A2;
D05-H12A;
EPI-CODES: S03-E14H4;

WEST

Generate Collection

L15: Entry 6 of 66

File: USPT

Dec 26, 2000

DOCUMENT-IDENTIFIER: US 6165464 A

TITLE: Monoclonal antibodies directed to the HER2 receptor

APD:

19980317

DEPR:

The ability of any particular antibody to mediate lysis of the tumor cell target by complement activation and/or ADCG can be assayed. The tumor cells of interest are grown and labeled in vivo; the antibody is added to the tumor cell culture in combination with either serum complement or immune cells which may be activated by the antigen antibody complexes. Cytolysis of the target tumor cells is detected by the release of label from the lysed cells. In fact, antibodies can be screened using the patient's own serum as a source of complement and/or immune cells. The antibody that is capable of activating complement or mediating ADCC in the in vitro test can then be used therapeutically in that particular patient.

DEPR:

The selection of an antibody subclass for therapy will depend upon the nature of the tumor antigen. For example, an IgM may be preferred in situations where the antigen is highly specific for the tumor target and rarely occurs on normal cells. However, where the tumor-associated antigen is also expressed in normal tissues, albeit at much lower levels, the IgG subclass may be preferred for the following reason: since the binding of at least two IgG molecules in close proximity is required to activate complement, less complement mediated damage may occur in the normal tissues which express smaller amounts of the antigen and, therefore, bind fewer IgG antibody molecules. Furthermore, IgG molecules by being smaller may be more able than IgM molecules to localize to tumor tissue.

WEST

Generate Collection

L15: Entry 8 of 66

File: USPT

Oct 31, 2000

DOCUMENT-IDENTIFIER: US 6140490 A

TITLE: High affinity nucleic acid ligands of complement system proteins

APD:

19980212

BSPR:

Activation of the Complement System can and has been used for therapeutic purposes. Antibodies which were produced against tumor cells were then used to activate the Complement System and cause tumor rejection. Also, the Complement System is used together with polyclonal or monoclonal antibodies to eliminate unwanted lymphocytes. For example, anti-lymphocyte globulin or monoclonal anti-T-cell antibodies are used prior to organ transplantation to eliminate lymphocytes which would otherwise mediate rejection.

WEST**End of Result Set**☐

Generate Collection

L36: Entry 2 of 2

File: USPT

Jan 22, 1991

DOCUMENT-IDENTIFIER: US 4986979 A

TITLE: Imaging tissue sites of inflammation

ORPL:

Collet et al., "Scintigraphic Detection in Mice of Inflammatory Lesions and Tumors by an Indium-Labelled Monoclonal Antibody Directed Against Mac-1 Antigen", Cancer Immunol. Immunother., 26: 237-242, 1988.

WEST

Generate Collection

L38: Entry 5 of 6

File: USPT

Mar 2, 1999

DOCUMENT-IDENTIFIER: US 5877295 A

TITLE: Antibodies which bind a subpopulation of Mac-1 (CD11b/CD18) molecules which mediate neutrophil adhesion to ICAM-1 and fibrinogen

DEPR:

The present invention further provides methods of selectively killing expressing activated Mac-1 cells. In detail, cells expressing activated Mac-1 can be selectively killed by contacting them with a "toxin derivatized antibody" which is capable of binding to activated Mac-1 but is substantially incapable of binding to non-activated Mac-1. As described above, the antibody derivatives of the present invention include antibodies which are conjugated to toxic molecules such as the ricin A chain. The present procedure provides a means of both treating Mac-1 dependent biological process by selectively killing the myeloid cells which mediate the process as well as a means of selectively killing tumor cells expressing activated Mac-1.

DEPR:

The present invention further provides methods of selectively removing cells from fluids or tissues which contain activated Mac-1 on their cell surface. In detail, stimulated myeloid cells which contain activated Mac-1 can be selectively removed from a fluid or tissue, such as a patient's blood, by passing the fluid over an immobilized antibody which is capable of binding to activated Mac-1 present on stimulated myeloid cells but is substantially incapable of binding to non-activated Mac-1 or resting myeloid cells. For example, stimulated myeloid cells or tumor cells expressing activated Mac-1 can be removed from a patient's blood by subjecting the patient to leukophoresis in which the leukophoresis contacts the patient's blood with an immobilized, activation specific anti-Mac-1 antibody.

Print Request Result(s)

Printer Name: cm1_8e12_gbelptr
Printer Location: cm1__8e12

- US005877295: Ok

BEST AVAILABLE COPY

<u>S3730</u>	<u>U</u>	USPT	(c3-bi) or (c-3-b-i) or (c-3bi))) or (antibod\$3 near4 (C3 or C3b(i) or (c-3-bi) or (c3-bi) or (c-3-b-i) or (c-3bi)))	15:50:35
<u>S3729</u>	<u>U</u>	USPT	antibod\$3 near4 (C3 or C3b(i) or (c-3-bi) or (c3-bi) or (c-3-b-i) or (c-3bi))	2001-10-13 15:50:15
<u>S3728</u>	<u>U</u>	USPT	anti adj (C3 or C3b(i) or (c-3-bi) or (c3-bi) or (c-3-b-i) or (c-3bi)) C3 or C3b(i) or (c-3-bi) or (c3-bi) or (c-3-b-i) or (c-3bi) C3 or C3(?)	2001-10-13 15:49:57 2001-10-13 15:49:32 2001-10-13
<u>S3727</u>	<u>U</u>	USPT		

BEST AVAILABLE COPY

(FILE 'HOME' ENTERED AT 15:17:22 ON 13 OCT 2001)

FILE 'MEDLINE, BIOSIS, CANCERLIT' ENTERED AT 15:17:39 ON 13 OCT 2001

L1 107211 S C3 OR C3##
L2 1386 S ANTI(W)L1
L3 2204 S L1(3A)ANTIBOD?
L4 2718 S L1(4A)ANTIBOD?
L5 3608 S L4 OR L2
L6 422 S L5(S) (CANCER# OR TUMOR# OR TUMOUR#)
L7 391 S L6 AND PY<1999
L8 144 S L7(S)COMPLEMENT
L9 75 DUP REM L8 (69 DUPLICATES REMOVED)
L10 121 S L5(S) (HODGKIN## OR MYELOMA# OR SARCOMA# OR FIBROSACROMA OR M
L11 138 S L5(S) (CARCINOMA# OR ADENOCARCINOMA OR GLIOMA OR ASTROCYTOMA
L12 299 S L5(S) (LEUKEMIA# OR LYMPHOMA# OR (POLYCYTHEMIA(W)VERA) OR MAL
L13 479 S L10 OR L11 OR L12
L14 158 S L13(S)COMPLEMENT
L15 135 S L6(S)COMPLEMENT
L16 246 S L14 OR L15
L17 232 S L16 AND PY<1999
L18 128 DUP REM L17 (104 DUPLICATES REMOVED)
L19 73 S L5(S) (MELANOMA)
L20 16 S L19(S)COMPLEMENT
L21 16 S L20 AND PY<1999
L22 9 DUP REM L21 (7 DUPLICATES REMOVED)
L23 2 S L22 NOT L18

=> d history

(FILE 'HOME' ENTERED AT 16:53:29 ON 13 OCT 2001)

FILE 'MEDLINE, BIOSIS, CANCERLIT' ENTERED AT 16:53:48 ON 13 OCT 2001

L1 9665 S CR3 OR IC3B OR (COMPLEMENT RECEPTOR 3) OR (CR-3) OR (I-C3B)
O
L2 11040 S CR3 OR IC3B OR (COMPLEMENT RECEPTOR 3) OR (CR-3) OR (I-C3B)
O
L3 533 S ANTI(W)L2
L4 811 S L2(3A)ANTIBOD?
L5 1077 S L3 OR L4
L6 189 S L5(S) (CANCER# OR TUMOR# OR TUMOUR# OR CARCINOMA# OR LYMPHOMA
L7 20 S L5(S) (ADENOCARCINOMA OR HODGKIN## OR FIBROSARCOMA OR ENDOTHE
L8 193 S L6 OR L7
L9 161 S L8 AND PY<1999
L10 67 DUP REM L9 (94 DUPLICATES REMOVED)

WEST

Searches for User *kcanella* (Count = 3766)

Queries 3717 through 3766.

Latest

Prev

Next

Oldest

Edit

Help

Return

Main Menu

Logout

S #	Updt	Database	Query	Time	Comment
<u>S3766</u>	<u>U</u>	USPT	(((anti adj (CR3 or (cr-3) or (complement adj receptor adj 3) or iC3b or (i-C3b) or (i-C-3b) or (i-c-3-b) or (ic-3b) or (ic3-b) or mac1 or (mac-1) or CD11b/18 or CD18/11b or CD11bCD18 or (CD11b-CD18) or (CD11b/CD18)))or (antibod\$3 near4 (CR3 or (cr-3) or (complement adj receptor adj 3) or iC3b or (i-C3b) or (i-C-3b) or (i-c-3-b) or (ic-3b) or (ic3-b) or mac1 or (mac-1) or CD11b/18 or CD18/11b or CD11bCD18 or (CD11b-CD18) or (CD11b/CD18))))same (cancer\$1 or tumor\$1 or tumour\$1 or melanoma or lymphoma or leukemia or hodgkin\$s or (non-hodgkin\$2) or myeloma or \$sarcoma or \$carcinoma or \$blastoma or glioma or astrocytoma)) not (((anti adj (CR3 or (cr-3) or (complement adj receptor adj 3) or iC3b or (i-C3b) or (i-C-3b) or (i-c-3-b) or (ic-3b) or (ic3-b) or mac1 or (mac-1) or CD11b/18 or CD18/11b or CD11bCD18 or (CD11b-CD18) or (CD11b/CD18)))or (antibod\$3 near4 (CR3 or (cr-3) or (complement adj receptor adj 3) or iC3b or (i-C3b) or (i-C-3b) or (i-c-3-b) or (ic-3b) or (ic3-b) or mac1 or (mac-1) or CD11b/18 or CD18/11b or CD11bCD18 or (CD11b-CD18) or (CD11b/CD18))))with (cancer\$1 or tumor\$1 or tumour\$1 or melanoma or lymphoma or leukemia or hodgkin\$s or (non-hodgkin\$2) or myeloma or	2001-10-13 16:49:02	

<p><u>S3765</u> <u>U</u> USPT</p>	<p>\$sarcoma or \$scarcinoma or \$blastoma or glioma or astrocytoma))</p> <p>((anti adj (CR3 or (cr-3) or (complement 2001-10-13 adj receptor adj 3) or iC3b or (i-C3b) or 16:46:55 (i-C-3b) or (i-c-3-b) or (ic-3b) or (ic3-b) or mac1 or (mac-1) or CD11b/18 or CD18/11b or CD11bCD18 or (CD11b-CD18) or (CD11b/CD18)))or (antibod\$3 near4 (CR3 or (cr-3) or (complement adj receptor adj 3) or iC3b or (i-C3b) or (i-C-3b) or (i-c-3-b) or (ic-3b) or (ic3-b) or mac1 or (mac-1) or CD11b/18 or CD18/11b or CD11bCD18 or (CD11b-CD18) or (CD11b/CD18)))) same (cancer\$1 or tumor\$1 or tumour\$1 or melanoma or lymphoma or leukemia or hodgkin\$s or (non-hodgkin\$2) or myeloma or \$sarcoma or \$scarcinoma or \$blastoma or glioma or astrocytoma)</p>
<p><u>S3764</u> <u>U</u> USPT</p>	<p>((anti adj (CR3 or (cr-3) or (complement 2001-10-13 adj receptor adj 3) or iC3b or (i-C3b) or 16:44:45 (i-C-3b) or (i-c-3-b) or (ic-3b) or (ic3-b) or mac1 or (mac-1) or CD11b/18 or CD18/11b or CD11bCD18 or (CD11b-CD18) or (CD11b/CD18)))or (antibod\$3 near4 (CR3 or (cr-3) or (complement adj receptor adj 3) or iC3b or (i-C3b) or (i-C-3b) or (i-c-3-b) or (ic-3b) or (ic3-b) or mac1 or (mac-1) or CD11b/18 or CD18/11b or CD11bCD18 or (CD11b-CD18) or (CD11b/CD18)))) with (cancer\$1 or tumor\$1 or tumour\$1 or melanoma or lymphoma or leukemia or hodgkin\$s or (non-hodgkin\$2) or myeloma or \$sarcoma or \$scarcinoma or \$blastoma or glioma or astrocytoma)</p>
<p><u>S3763</u> <u>U</u> USPT</p>	<p>(anti adj (CR3 or (cr-3) or (complement 2001-10-13 adj receptor adj 3) or iC3b or (i-C3b) or 16:44:18 (i-C-3b) or (i-c-3-b) or (ic-3b) or (ic3-b) or mac1 or (mac-1) or CD11b/18 or CD18/11b or CD11bCD18 or (CD11b-CD18) or (CD11b/CD18))) or (antibod\$3 near4 (CR3 or (cr-3) or (complement adj receptor adj 3) or iC3b or (i-C3b) or (i-C-3b) or (i-c-3-b) or (ic-3b) or (ic3-b) or mac1 or (mac-1) or CD11b/18 or CD18/11b or CD11bCD18 or (CD11b-CD18) or (CD11b/CD18)))</p>
<p><u>S3762</u> <u>U</u> USPT</p>	<p>antibod\$3 near4 (CR3 or (cr-3) or 2001-10-13</p>

			(complement adj receptor adj 3) or iC3b 16:43:28 or (i-C3b) or (i-C-3b) or (i-c-3-b) or (ic-3b) or (ic3-b) or mac1 or (mac-1) or CD11b/18 or CD18/11b or CD11bCD18 or (CD11b-CD18) or (CD11b/CD18))	
<u>S3761</u>	<u>U</u>	USPT	anti adj (CR3 or (cr-3) or (complement 2001-10-13 adj receptor adj 3) or iC3b or (i-C3b) or 16:43:13 (i-C-3b) or (i-c-3-b) or (ic-3b) or (ic3-b) or mac1 or (mac-1) or CD11b/18 or CD18/11b or CD11bCD18 or (CD11b-CD18) or (CD11b/CD18))	
<u>S3760</u>	<u>U</u>	USPT	CR3 or (cr-3) or (complement adj 2001-10-13 receptor adj 3) or iC3b or (i-C3b) or 16:42:32 (i-C-3b) or (i-c-3-b) or (ic-3b) or (ic3-b) or mac1 or (mac-1) or CD11b/18 or CD18/11b or CD11bCD18 or (CD11b-CD18) or (CD11b/CD18)	
<u>S3759</u>	<u>U</u>	USPT	((anti adj cr1)or (antibod\$3 near4 cr1)) 2001-10-13 with (cancer\$1 or tumor\$1 or tumour\$1 16:37:31 or melanoma or lymphoma or leukemia or hodgkin\$s or (non-hodgkin\$2) or myeloma or \$sarcoma or \$carcinoma or \$blastoma or glioma or astrocytoma)	
<u>S3758</u>	<u>U</u>	USPT	(anti adj cr1) or (antibod\$3 near4 cr1) 2001-10-13 16:36:58	
<u>S3757</u>	<u>U</u>	USPT	antibod\$3 near4 cr1 2001-10-13 16:36:49	
<u>S3756</u>	<u>U</u>	USPT	anti adj cr1 2001-10-13 16:36:36	
<u>S3755</u>	<u>U</u>	JPAB,EPAB,DWPI	(anti adj (c3b or (cr-1) or (complement 2001-10-13 adj receptor adj 1) or CD35 or cr1)) or 16:35:47 (antibod\$3 near4 (anti adj (c3b or (cr-1) or (complement adj receptor adj 1) or CD35 or cr1)))	
<u>S3754</u>	<u>U</u>	JPAB,EPAB,DWPI	target\$3 near3 (anti adj (c3b or (cr-1) or 2001-10-13 (complement adj receptor adj 1) or 16:35:32 CD35 or cr1))	
<u>S3753</u>	<u>U</u>	JPAB,EPAB,DWPI	antibod\$3 near4 (anti adj (c3b or (cr-1) 2001-10-13 or (complement adj receptor adj 1) or 16:35:00 CD35 or cr1))	
<u>S3752</u>	<u>U</u>	JPAB,EPAB,DWPI	anti adj (c3b or (cr-1) or (complement 2001-10-13 adj receptor adj 1) or CD35 or cr1) 16:34:29	
<u>S3751</u>	<u>U</u>	JPAB,EPAB,DWPI	c3b or (cr-1) or (complement adj 2001-10-13 receptor adj 1) or CD35 or cr1 16:33:30	
<u>S3750</u>	<u>U</u>	JPAB,EPAB,DWPI	c3b or (cr-1) or (complement adj 2001-10-13 receptor adj 1) or CD35 16:33:06	
<u>S3749</u>	<u>U</u>	USPT	((anti adj (c3b or (cr-1) or (complement 2001-10-13	

			adj receptor adj 1) or CD35))or (antibod\$3 near4 (c3b or (cr-1) or (complement adj receptor adj 1) or CD35))) with (cancer\$1 or tumor\$1 or tumour\$1 or melanoma or lymphoma or leukemia or hodgkin\$s or (non-hodgkin\$2) or myeloma or \$sarcoma or \$carcinoma or \$blastoma or glioma or astrocytoma)	16:27:47
<u>S3748</u>	<u>U</u>	USPT	(anti adj (c3b or (cr-1) or (complement adj receptor adj 1) or CD35)) or (antibod\$3 near4 (c3b or (cr-1) or (complement adj receptor adj 1) or CD35))	2001-10-13 16:27:30
<u>S3747</u>	<u>U</u>	USPT	antibod\$3 near4 (c3b or (cr-1) or (complement adj receptor adj 1) or CD35)	2001-10-13 16:27:18
<u>S3746</u>	<u>U</u>	USPT	anti adj (c3b or (cr-1) or (complement adj receptor adj 1) or CD35)	2001-10-13 16:26:33
<u>S3745</u>	<u>U</u>	USPT	((c3b or (cr-1) or (complement adj receptor adj 1) or CD35)with (cancer\$1 or tumor\$1 or tumour\$1 or melanoma or lymphoma or leukemia or hodgkin\$s or (non-hodgkin\$2) or myeloma or \$sarcoma or \$carcinoma or \$blastoma or glioma or astrocytoma)) and @ad<19980910	2001-10-13 16:25:52
<u>S3744</u>	<u>U</u>	USPT	(c3b or (cr-1) or (complement adj receptor adj 1) or CD35) with (cancer\$1 or tumor\$1 or tumour\$1 or melanoma or lymphoma or leukemia or hodgkin\$s or (non-hodgkin\$2) or myeloma or \$sarcoma or \$carcinoma or \$blastoma or glioma or astrocytoma)	2001-10-13 16:25:15
<u>S3743</u>	<u>U</u>	USPT	c3b or (cr-1) or (complement adj receptor adj 1) or CD35	2001-10-13 16:24:17
<u>S3742</u>	<u>U</u>	USPT	((complement near activa\$4)with (cancer\$1 or tumor\$1 or tumour\$1 or melanoma or lymphoma or leukemia or hodgkin\$s or (non-hodgkin\$2) or myeloma or \$sarcoma or \$carcinoma or \$blastoma or glioma or astrocytoma)) and @ad<19980910	2001-10-13 16:08:35
<u>S3741</u>	<u>U</u>	USPT	(complement near activa\$4) with (cancer\$1 or tumor\$1 or tumour\$1 or melanoma or lymphoma or leukemia or hodgkin\$s or (non-hodgkin\$2) or myeloma or \$sarcoma or \$carcinoma or \$blastoma or glioma or astrocytoma)	2001-10-13 16:08:03

<u>S3740</u>	<u>U</u>	USPT	complement near activa\$4	2001-10-13 16:04:39
<u>S3739</u>	<u>U</u>	USPT	complement adj activation	2001-10-13 16:03:59
<u>S3738</u>	<u>U</u>	JPAB,EPAB,DWPI	((anti adj (C3 or C3b(i) or (c-3-bi) or (c3-bi) or (c-3-b-i) or (c-3bi)))or (antibod\$3 near4 (C3 or C3b(i) or (c-3-bi) or (c3-bi) or (c-3-b-i) or (c-3bi)))) and (cancer\$1 or tumor\$1 or tumour\$1 or melanoma or lymphoma or leukemia or hodgkin\$s or (non-hodgkin\$2) or myeloma or \$sarcoma or \$carcinoma or \$blastoma or glioma or astrocytoma)	2001-10-13 16:00:03
<u>S3737</u>	<u>U</u>	JPAB,EPAB,DWPI	(anti adj (C3 or C3b(i) or (c-3-bi) or (c3-bi) or (c-3-b-i) or (c-3bi))) or (antibod\$3 near4 (C3 or C3b(i) or (c-3-bi) or (c3-bi) or (c-3-b-i) or (c-3bi)))	2001-10-13 15:59:39
<u>S3736</u>	<u>U</u>	JPAB,EPAB,DWPI	antibod\$3 near4 (C3 or C3b(i) or (c-3-bi) or (c3-bi) or (c-3-b-i) or (c-3bi))	2001-10-13 15:59:27
<u>S3735</u>	<u>U</u>	JPAB,EPAB,DWPI	anti adj (C3 or C3b(i) or (c-3-bi) or (c3-bi) or (c-3-b-i) or (c-3bi))	2001-10-13 15:58:54
<u>S3734</u>	<u>U</u>	JPAB,EPAB,DWPI	C3 or C3b(i) or (c-3-bi) or (c3-bi) or (c-3-b-i) or (c-3bi)	2001-10-13 15:58:34
<u>S3733</u>	<u>U</u>	USPT	((anti adj (C3 or C3b(i) or (c-3-bi) or (c3-bi) or (c-3-b-i) or (c-3bi)))or (antibod\$3 near4 (C3 or C3b(i) or (c-3-bi) or (c3-bi) or (c-3-b-i) or (c-3bi))))with (cancer\$1 or tumor\$1 or tumour\$1 or melanoma or lymphoma or leukemia or hodgkin\$s or (non-hodgkin\$2) or myeloma or \$sarcoma or \$carcinoma or \$blastoma or glioma or astrocytoma)) and @ad<19980910	2001-10-13 15:54:54
<u>S3732</u>	<u>U</u>	USPT	((anti adj (C3 or C3b(i) or (c-3-bi) or (c3-bi) or (c-3-b-i) or (c-3bi)))or (antibod\$3 near4 (C3 or C3b(i) or (c-3-bi) or (c3-bi) or (c-3-b-i) or (c-3bi)))) with (cancer\$1 or tumor\$1 or tumour\$1 or melanoma or lymphoma or leukemia or hodgkin\$s or (non-hodgkin\$2) or myeloma or \$sarcoma or \$carcinoma or \$blastoma or glioma or astrocytoma)	2001-10-13 15:53:53
<u>S3731</u>	<u>U</u>	USPT	(anti adj (C3 or C3b(i) or (c-3-bi) or	2001-10-13